Synapse-regenerating drug could reverse decline in Alzheimer’s
![](https://www.spinogenix.com/wp-content/uploads/2024/06/DDW-logo-black-1-1.png)
FDA OKs Phase 1/2 clinical trial of small molecule SPG302 in ALS
![](https://www.spinogenix.com/wp-content/uploads/2024/06/ALSnewstoday-1-1.png)
FDA clears investigational new drug application for clinical trial of ALS pill
![](https://www.spinogenix.com/wp-content/uploads/2024/04/Healio-Logo-1.jpg)
Synapse-Generating Small Molecule for ALS Receives Nod from FDA for Clinical Trial
![](https://www.spinogenix.com/wp-content/uploads/2024/05/practical.jpg)
FDA grants IND clearance for Spinogenix’s ALS treatment trial
![](https://www.spinogenix.com/wp-content/uploads/2024/04/CTA.jpg)
Breakthrough synapse-regenerating ALS pill moves to phase 2 human trials
![](https://www.spinogenix.com/wp-content/uploads/2024/05/new-atlas.jpg)
Spinogenix’s Daily Pill SPG302 Receives FDA IND Nod for ALS Treatment
![](https://www.spinogenix.com/wp-content/uploads/2024/05/health-pharma.png)
FDA grants orphan designation to Fragile X syndrome therapeutic
![](https://www.spinogenix.com/wp-content/uploads/2024/04/Healio-Logo-1.jpg)
Spinogenix’s SPG601 Earns Orphan Drug Designation for Fragile X Syndrome
![](https://www.spinogenix.com/wp-content/uploads/2024/05/news-p-logo-e1716493682184.png)
FDA clears investigational new drug application for Fragile X treatment
![](https://www.spinogenix.com/wp-content/uploads/2024/04/Healio-Logo-1.jpg)